Qilian International Holding Group (BGM) Competitors $8.50 0.00 (0.00%) (As of 12/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends BGM vs. FULC, DMAC, ZNTL, ATAI, ACRV, ACRS, XBIT, BMEA, SBTX, and LFVNShould you be buying Qilian International Holding Group stock or one of its competitors? The main competitors of Qilian International Holding Group include Fulcrum Therapeutics (FULC), DiaMedica Therapeutics (DMAC), Zentalis Pharmaceuticals (ZNTL), Atai Life Sciences (ATAI), Acrivon Therapeutics (ACRV), Aclaris Therapeutics (ACRS), XBiotech (XBIT), Biomea Fusion (BMEA), Silverback Therapeutics (SBTX), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical preparations" industry. Qilian International Holding Group vs. Fulcrum Therapeutics DiaMedica Therapeutics Zentalis Pharmaceuticals Atai Life Sciences Acrivon Therapeutics Aclaris Therapeutics XBiotech Biomea Fusion Silverback Therapeutics LifeVantage Fulcrum Therapeutics (NASDAQ:FULC) and Qilian International Holding Group (NASDAQ:BGM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations. Which has more volatility & risk, FULC or BGM? Fulcrum Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Comparatively, Qilian International Holding Group has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Does the MarketBeat Community favor FULC or BGM? Fulcrum Therapeutics received 98 more outperform votes than Qilian International Holding Group when rated by MarketBeat users. CompanyUnderperformOutperformFulcrum TherapeuticsOutperform Votes9861.25% Underperform Votes6238.75% Qilian International Holding GroupN/AN/A Do institutionals and insiders believe in FULC or BGM? 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 4.1% of Fulcrum Therapeutics shares are owned by insiders. Comparatively, 58.7% of Qilian International Holding Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher earnings and valuation, FULC or BGM? Qilian International Holding Group has lower revenue, but higher earnings than Fulcrum Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum Therapeutics$80.87M2.90-$97.33M-$0.31-14.03Qilian International Holding Group$29.87M2.06-$7.78MN/AN/A Is FULC or BGM more profitable? Qilian International Holding Group's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -7.31% -6.74% Qilian International Holding Group N/A N/A N/A Do analysts recommend FULC or BGM? Fulcrum Therapeutics presently has a consensus target price of $9.33, suggesting a potential upside of 114.56%. Given Fulcrum Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Fulcrum Therapeutics is more favorable than Qilian International Holding Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 1 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20Qilian International Holding Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer FULC or BGM? In the previous week, Fulcrum Therapeutics had 2 more articles in the media than Qilian International Holding Group. MarketBeat recorded 3 mentions for Fulcrum Therapeutics and 1 mentions for Qilian International Holding Group. Fulcrum Therapeutics' average media sentiment score of 0.62 beat Qilian International Holding Group's score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Qilian International Holding Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryFulcrum Therapeutics beats Qilian International Holding Group on 10 of the 14 factors compared between the two stocks. Ad Porter & CompanyI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Qilian International Holding Group News Delivered to You Automatically Sign up to receive the latest news and ratings for BGM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BGM vs. The Competition Export to ExcelMetricQilian International Holding GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.43M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E RatioN/A10.5990.0517.18Price / Sales2.06196.061,116.25117.05Price / Cash26.7157.1643.1037.85Price / BookN/A5.094.784.78Net Income-$7.78M$151.83M$120.31M$225.60M7 Day Performance-1.16%-2.14%-1.92%-1.23%1 Month Performance21.43%-4.56%13.65%0.46%1 Year PerformanceN/A8.87%28.34%15.24% Qilian International Holding Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BGMQilian International Holding GroupN/A$8.50flatN/AN/A$61.43M$29.87M0.00298News CoverageFULCFulcrum Therapeutics1.7128 of 5 stars$4.42+11.6%$9.33+111.2%-24.6%$238.41M$80.87M-13.68100Positive NewsDMACDiaMedica Therapeutics0.8091 of 5 stars$5.40+0.4%$7.00+29.6%+127.3%$230.90MN/A-9.6120News CoverageGap DownZNTLZentalis Pharmaceuticals2.0028 of 5 stars$3.22+4.2%$10.00+210.6%-79.0%$229.46MN/A-1.24160ATAIAtai Life Sciences1.8886 of 5 stars$1.35-1.1%$9.00+569.1%-8.5%$225.69M$331,000.00-1.6883Positive NewsACRVAcrivon Therapeutics0.9469 of 5 stars$7.04-0.3%$23.67+236.2%+37.8%$219.20MN/A-2.6158News CoverageGap DownACRSAclaris Therapeutics3.856 of 5 stars$3.02-6.2%$8.80+191.4%+169.3%$215.72M$31.25M-6.1986Positive NewsXBITXBiotechN/A$6.97+0.3%N/A+59.9%$212.45M$4.01M-6.44100BMEABiomea Fusion3.9054 of 5 stars$5.85+3.7%$39.36+572.9%-71.0%$212.00MN/A-1.4150Analyst ForecastSBTXSilverback TherapeuticsN/A$5.87+1.0%N/A+121.8%$211.66MN/A-4.9283News CoverageLFVNLifeVantage4.5473 of 5 stars$16.80+4.7%N/A+176.9%$210.42M$196.01M50.13260Analyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies FULC Competitors DMAC Competitors ZNTL Competitors ATAI Competitors ACRV Competitors ACRS Competitors XBIT Competitors BMEA Competitors SBTX Competitors LFVN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BGM) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qilian International Holding Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Qilian International Holding Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
